Angiotensin-Converting Enzyme Inhibitors
"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
| Descriptor ID |
D000806
|
| MeSH Number(s) |
D27.505.519.389.745.085
|
| Concept/Terms |
Angiotensin-Converting Enzyme Inhibitors- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Converting Enzyme Inhibitors
- Inhibitors, Kininase II
- Kininase II Antagonists
- Kininase II Inhibitors
- Angiotensin I-Converting Enzyme Inhibitors
- Angiotensin I Converting Enzyme Inhibitors
- Antagonists, Angiotensin-Converting Enzyme
- Antagonists, Angiotensin Converting Enzyme
- Antagonists, Kininase II
- Inhibitors, ACE
- ACE Inhibitors
- Inhibitors, Angiotensin-Converting Enzyme
- Enzyme Inhibitors, Angiotensin-Converting
- Inhibitors, Angiotensin Converting Enzyme
- Angiotensin-Converting Enzyme Antagonists
- Angiotensin Converting Enzyme Antagonists
- Enzyme Antagonists, Angiotensin-Converting
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".
This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 2 | 2 | 4 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 4 | 5 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 2 | 3 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 4 | 3 | 7 |
| 2017 | 29 | 42 | 71 |
| 2018 | 27 | 30 | 57 |
| 2019 | 17 | 16 | 33 |
| 2020 | 120 | 92 | 212 |
| 2021 | 33 | 44 | 77 |
| 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.
-
Angiotensin-converting enzyme 2: a key enzyme in key organs. J Cardiovasc Med (Hagerstown). 2022 01 01; 23(1):1-11.
-
Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis. Am J Health Syst Pharm. 2021 Dec 09; 78(24):2245-2255.
-
Role of Hypertension on the Severity of COVID-19: A Review. J Cardiovasc Pharmacol. 2021 11 01; 78(5):e648-e655.
-
In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients. J Clin Invest. 2021 10 01; 131(19).
-
Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice. Zool Res. 2021 Sep 18; 42(5):633-636.
-
Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis. Crit Care Med. 2021 09 01; 49(9):1558-1566.
-
Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial. Trials. 2021 Aug 28; 22(1):573.
-
Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacol Res. 2021 11; 173:105848.
-
Synthesis of novel calcium channel blockers with ACE2 inhibition and dual antihypertensive/anti-inflammatory effects: A possible therapeutic tool for COVID-19. Bioorg Chem. 2021 11; 116:105272.
-
Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe? Clin Exp Hypertens. 2022 Jan 02; 44(1):1-10.